News
In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro and Zepbound) lost more weight and inches from their waist than those who ...
While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...
Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...
The U.S. Food and Drug Administration (FDA) has issued a warning to patients and healthcare professionals regarding the use ...
For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...
Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name ...
The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...
17h
Newser on MSNMounjaro Beats Ozempic in Head-to-Head StudyMounjaro wins bragging rights over Ozempic in a new weight-loss study—though it's one that was funded by the maker of ...
19h
Study Finds on MSNWeight Loss Showdown: Mounjaro (Tirzepatide) Trounces Wegovy in Head-to-Head TrialIn a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...
Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...
As a Biden administration ban on so-called “junk fees” took effect Monday, Ticketmaster said it would start displaying the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results